Physician profile
James E Seeley
NPI 1568448736
$2,523.05
in general payments reported to CMS, 2019-2025
23 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.18 · 2020: $310 · 2021: $260 · 2022: $465 · 2023: $420 · 2024: $629 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $812.52 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $229.18 | 2020-2023 | Jardiance, Emgality, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $221.95 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $220.78 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $202.12 | 2022-2024 | Ubrelvy |
| Pfizer INC. | $121.40 | 2019-2025 | |
| Novo Nordisk INC | $100.91 | 2021-2023 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $94.67 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.12 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $64.85 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.03 | 2022 | |
| Sumitomo Pharma America, INC. | $53.08 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $43.82 | 2023-2024 | Quviviq |
| Abbott Laboratories | $34.75 | 2021-2022 | |
| Exact Sciences Corporation | $31.64 | 2023-2024 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.56 | 2022 | |
| Allergan, INC. | $24.26 | 2020 | |
| Boston Scientific Corporation | $23.82 | 2021 | |
| Eisai INC. | $17.14 | 2025 | |
| Merck Sharp & Dohme LLC | $16.34 | 2019 | |
| Esperion Therapeutics, INC. | $15.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.65 | 2022 | |
| Amgen INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Seeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.